REFERENCES
- Moolenaar WH. Lysophosphatidic acid, a multi-functional phospholipid messenger. J Biol Chem 1995; 270: 12949–52.
- Moolenaar WH. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol 1994; 4: 213–9.
- Xu Y, Ouk Kim S, Liao D, Katz S, Pelech SL. Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysopho-sphatidic acid in rat cardiomyocytes. Biochem Pharmacol 2000; 59: 1163–71.
- Eichholtz T. The bioactive phospholipid lysopho-sphatidic acid is released from activated platelets. Biochem J 1993; 291: 677–80.
- Goetzl EJ. Distinctive expression and functions of the type4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999; 59: 5370 — 5.
- Sasagawa T. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 1999; 34: 17–21.
- He LJ, Han BM, Chen X, Li HW, Shen LH. Study on the role of lysophophatidic acid and its receptor in heart remodeling. China Med Trib 2001; 27: 7.
- Chen JH, Zou F, Wang ND, Xie SW, Zhang X. Production and application of LPA polyclonal antibody. Bioorg Med Chem Lett 2000; 10: 1691.
- Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 1992; 267: 21360— 7.
- Panetti TS, Magnusson MK, Peyruchaud O, Zhang Q, Cooke ME, Sakai T. Modulation of cell interactions with extracellular matrix by lysop-hosphatidic acid and sphingosine 1-phosphate. Prostaglandins 2001; 64: 93–106.
- Ediger TL, Toews ML. Dual effects of lysopho-sphatidic acid on human airway smooth muscle cell proliferation and survival. Biochim Biophys Acta 2001; 1531: 59–67.
- Xu Y, Shen ZZ, Wiper DW, Wu MZ, Morton RE, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719–23.
- Stith BJ, Hall J, Ayres P, Waggoner L, Moore JD, Shaw WA. Quantification of major classes of Xenopus phospholipids by high performance liquid chromatography with evaporative light scattering detection. J Lipid Res 2000; 41: 1448–54.
- Xiao YJ, Chen YH, Kennedy AW, Belinson J, Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ioniza-tion mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 2000; 905: 243–59.
- Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P. A simple and highly sensitive radioenzymatic assay for lysophosphati-dic acid quantification. J Lipid Res 2000; 41: 1947 — 51.
- Okusa MD, Ye H, Huang L, Sigismund L, Macdonald T, Lynch KR. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2003; 285: F565–74.
- Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001; 33: 1713–7.
- De Vries B, Matthijsen RA, Van Bijnen AA, Wolfs TG, Buurman WA. Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activa-tion. Am J Pathol 2003; 163: 47–56.